RealFeedApp Argenx buys protein specialist to develop oral medicines
Argenx agreed to buy Unnatural Products with a $550 million upfront payment and potential additional payments totaling $595 million. The acquired platform leverages machine learning to engineer macrocyclic peptides that bind effectively to complex proteins while remaining swallowable.
- Field
- business and funding
- What they did
- Argenx, a Dutch biotechnology company focused on antibody drugs, agreed to acquire Unnatural Products' platform for engineering macrocyclic peptides in a deal potentially worth over a billion dollars.
- Why it matters
- The acquisition will enable Argenx to develop oral, long-lasting medicines for serious immune-mediated diseases, leveraging the peptides' ability to bind more effectively to complex proteins while remaining small enough to be swallowed.
#macrocyclic peptides#machine learning#biotech acquisition#argenx#unnatural products
